Inovio Pharmaceuticals, Inc. (INO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7300 |
| Open | 1.7700 |
| Bid | 1.8700 x 38500 |
| Ask | 1.8800 x 29200 |
| Day's Range | 1.7200 - 1.8900 |
| 52 Week Range | 1.3800 - 9.9600 |
| Volume | |
| Avg. Volume | 6,369,822 |
| Market Cap | 432.887M |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5420 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for INO
Related Research
- Inovio Pharmaceuticals, Inc.Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.RatingFair ValueEconomic Moat6 days agoMorningstar
- PR Newswire
INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that in connection with the hiring of Dr. Michael John Sumner as Chief Medical Officer, announced on June 27, 2022, the Compensation Committee of INOVIO's Board of Directors approved equity grants to Dr. Sumner as inducement awards under INOVIO's 2022 Inducement Plan (the "In
- American City Business Journals
Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options
This week's Lab Notes has items on a Chester County company's ongoing pursuit of approval for its lead drug candidate, a Bucks County company exploring its options after generating positive study results for an experimental angina drug, two local life sciences companies naming new chief medical officers, and more.
- Motley Fool
Why Inovio Pharmaceuticals Stock Topped the Market on Monday
Inovio Pharmaceuticals (NASDAQ: INO) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. Previous to that, he worked in various positions at U.K. pharmaceutical company Shire in a stint that lasted roughly six years, and also held positions at Novartis and Novo Nordisk.
